Clinical Trial ID: NCT05445778
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab (GLORIOSA)
Status
Open
Conditions
Other
Phases
III
Age Group
Adult
Main Investiagtor
Hand, Lauren
Practice
Gyn
Scope
National
Participating Institutions
Baptist MD Anderson Cancer Center
Nct ID Number
NCT05445778
Secondary Trial ID Number
GOG-3078
Keywords
Treatment